Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
China and Russia Supply Vaccines: Why the Confidence in US and EU Pharmaceuticals Increases.????
https://pennystocks.news/china-and-russia-supply-vaccines-why-the-confidence-in-us-and-eu-pharmaceuticals-increases-azn/
They are one of the leaders but need a positive confirmation about their covid vaccine research
9:49 pm ET September 16, 2020 (Benzinga) Print
AstraZeneca Plc’s (NYSE: AZN) vaccine didn't likely cause the adverse events that suspended the late-stage human trials of the drug, according to Oxford University.
What Happened: Volunteers in the British drugmaker’s ChAdOx1 nCoV-19 vaccine trial developed unexplained neurological symptoms including changed sensation or weakness in limbs, according to a participant information document published by Oxford, which is co-developing the vaccine with AstraZeneca.
“After independent review, these illnesses were either considered unlikely to be associated with the vaccine or there was insufficient evidence to say for certain that the illnesses were or were not related to the vaccine,” Oxford said, as first reported by Reuters.
Independent reviewers recommended the vaccinations should continue after reviewing each of these cases, according to the document.
Why It Matters: AstraZeneca has resumed trials of the vaccine in the United Kingdom, India, South Africa, and Brazil.
Trials haven't yet resumed in the United States. The Food and Drug Administration Commissioner Stephen Hahn said that his agency is “going to do very significant work with the company to figure out if there’s a significant safety issue or not.”
it should move up nicely - they seem to still be on one of the leaders in the Pharma pack
Azn.held their ground even though they had a major setback .
Lets see what this week bring s
Yep, saw that too so things don't look so bad anymore.
The Oxford vaccine
Astrazeneca could screen out vaccine recipients for John Cunningham virus (JCV) prior to getting the vaccine.
the pause is due to the nano particles in the vaccine that damage your spine, those nano particles can react with radio waves and fry you from the inside IMO in my opinion
Is the pause due to Progressive Multifocal Leukoencephalopathy (PML). Progressive Multifocal Leukoencephalopathy (PML) is a neurological disorder that can be a side effect of various immunological treatments. Patients may be may be tested for the JC virus before getting the Oxford vaccine to prevent PML.
Other drugs have been FDA approved even though during trials some small percentage of patients developed PML.
Hopefully the benefits of the vaccine far out way the risk.
Good luck and GOD bless,
Nothing wrong: totally normal and professional procedure
https://pennystocks.news/pharmaceuticals-are-rising-why-astrazeneca-is-not-in-trouble-azn/
Dan: this is not unusual they have to investigate what really caused the subject to have this reaction- what's more, it shows that AZN is not rushing thru the approval, but are carefully digesting and investigating the data. From what I understand, they are continuing the study next week. So it has not been discontinued. Stock will hold ground or rise. JMO
Wow! I saw Australia was on board etc, happy I didn’t buy into a position. Here as I am watching the stock market correct and this was on my watch list.
AZN
$AZN
My mom called me and told me she saw it on the news.. Not good with unexplained illnesses...
This is BAD......really bad! Word on the street is may be MONTHS before vaccine trials continue. I sure hope that’s wrong.
The US, UK and Australia seem to trust on AZN. Good prospects!
https://pennystocks.news/new-deals-with-prosperous-countries-for-this-large-pharmaceutist-a-race-won-azn/
It seems AstraZeneca is still on pole position in the EU!
https://pennystocks.news/is-astrazeneca-the-vaccine-pioneer-of-the-european-union-azn/?preview=true&_thumbnail_id=76769
WASHINGTON -- The Trump administration is asking states to speed up approval for vaccine distribution sites by Nov. 1, the latest sign the federal government is eager to get a vaccine out before the end of the year.
Centers for Disease Control and Prevention Director Robert Redfield urged state governors to remove barriers to building permits for distribution sites for use by McKesson Corp. and the drug wholesaler's subsidiaries, according to an Aug. 27 letter. The Dallas-based company has a deal with the federal government to distribute a coronavirus vaccine when it becomes available.
"CDC urgently requests your assistance in expediting applications for these distribution facilities, and, if necessary, asks that you consider waiving requirements that would prevent these facilities from becoming fully operational by Nov. 1, 2020," read the letter from Dr. Redfield to the states.
The administration has been pushing for a coronavirus vaccine. Food and Drug Administrator Stephen Hahn said in a recent interview with the Financial Times that an emergency authorization for a vaccine could be appropriate even before the vaccine has completed Phase 3 clinical trials.
An FDA vaccine advisory committee will meet Oct. 22 to discuss the development, authorization and licensing of vaccines to prevent Covid-19.
The CDC also provided documents to states outlining some of the most detailed descriptions to date of a vaccine rollout plan
The agency said vaccines would either be approved as licensed vaccines or under emergency-use authorization and would likely require two administrations.
"Vaccine and ancillary supplies will be procured and distributed by the federal government at no cost to enrolled Covid-19 vaccination providers, " the documents state.
They also state that jurisdictions must be prepared to immediately vaccinate identified critical populations when the earliest Covid-19 vaccine doses are available.
A screening tool on the CDC website will help individuals determine their eligibility for a vaccine and direct them to a vaccine finder.
One scenario described the availability of about two million doses by the end of October and another 10 million to 20 million doses available by the end of November, according to the documents sent to states.
The Trump administration has prioritized a vaccine through an initiative it has dubbed Operation Warp Speed, and the Department of Health and Human Services has said it is preparing to launch a November public-awareness campaign across TV, radio and social media, focusing on vaccine safety, efficacy and patient hesitancy.
Dr. Hahn's comments and the push to set up distribution sites by Nov. 1 has concerned some public-health experts who worry a vaccine could be rushed because of political pressure before it is determined to be fully safe. Election Day is Nov. 3, though many voters will have cast their ballots by mail well before that date.
Trump administration officials have pushed back on the criticism, saying Americans can trust the vaccine process.
"We all recognize that the public will have confidence in our decisions only if they are supported by the science. My personal commitment is to assure that all decisions meet FDA's standard. The patient and the public always come first," Dr. Hahn tweeted on Tuesday.
The administration on Tuesday ramped up its messaging on the safety of a vaccine. HHS Secretary Alex Azar and Dr. Moncef Slaoui, chief adviser to Operation Warp Speed, issued a release saying the optimistic target for a safe and effective vaccine is no later than January 2021.
"While one can never guarantee success in any scientific endeavor, it is now becoming increasingly likely we will deliver this historic victory for the American people and the world," they said in the release.
The administration this week said it won't join an international vaccine effort because it is co-led by the World Health Organization. President Trump has criticized WHO, saying it is too beholden to China.
Some public-health leaders have said the decision could mean the U.S. would have trouble getting vaccine doses if another country develops a successful vaccine more quickly. It also puts more pressure on the U.S. to develop a vaccine.
McKesson, one of the world's largest drug wholesalers, said last month that it would be a centralized distributor of future Covid-19 vaccines and the supplies needed to administer vaccinations.
"Vaccines and related supplies will be delivered to point-of-care sites across the country at the U.S. government's direction," the company said in an Aug. 14 press release.
National distribution plans call for prioritizing front-line health workers and people especially vulnerable to more severe symptoms of Covid-19.
Three vaccines are in Phase 3 clinical trials in the U.S. They are an AstraZeneca PLC vaccine developed with Oxford University, a vaccine from Moderna Inc., and a candidate from Pfizer Inc. and German-based BioNTech SE.
Thirty-five percent of Americans said they wouldn't get a free FDA-approved vaccine if it were ready, according to a poll released Aug. 7 by Gallup. Four in 10 nonwhite Americans and nearly half of Republicans said they wouldn't get vaccinated, while Democrats were more likely to say they would.
--Jared Hopkins contributed to this article.
Write to Stephanie Armour at stephanie.armour@wsj.com
Why AstraZeneca Can Climb Again When Focusing On This Promising Treatment:
https://pennystocks.news/why-astrazeneca-can-climb-again-when-focusing-on-this-promising-treatment-azn/
Things looking better and better
Trump just announced that AZN is entering phase 111 re the vaccine. Should move the stock tomorrow, along with them being added to the S&P500. We shall see.
AZN was just added to the S&500. Maybe we'll start to get some action
Amarin: Use of Vascepa with Crestor
https://www.ajmc.com/view/patients-take-different-statins-but-vascepa-benefits-are-the-same
Amarin: Evaporate trial results; Vascepa Effect on Arterial Plaque
https://www.acc.org/latest-in-cardiology/clinical-trials/2019/11/15/17/46/evaporate?utm_medium=social&utm_source=twitter_post&utm_campaign=esc20&utm_content=
https://investor.amarincorp.com/news-releases/news-release-details/vascepar-icosapent-ethyl-reported-significantly-reduce-coronary
https://academic.oup.com/eurheartj
https://doi.org/10.1093/eurheartj/ehaa652
The 2020 Upside: A Perfect Storm for Psychedelics Investors
Click Here to read Article
10,000 people in uk given experimental vaccine from astrazeneca/Oxford.
News: $AZN Moderna Receives Additional $472 Million to Develop Coronavirus Vaccine
Moderna 's (NASDAQ: MRNA) lucrative relationship with the U.S. government took another big step forward on Sunday. The Biomedical Advanced Research and Development Authority (BARDA) amended its contract with the clinical-stage biotechnology company for an additional commitment of up to $472 m...
Find out more AZN - Moderna Receives Additional $472 Million to Develop Coronavirus Vaccine
News: $AZN Here's Your Guide to the Coronavirus Vaccine Leaders
Moderna (NASDAQ: MRNA) , Inovio Pharmaceuticals (NASDAQ: INO) , and Novavax (NASDAQ: NVAX) have become household names these days -- at least to investors betting on who may win the coronavirus vaccine race. More than 20 companies and research institutes have brought their candidates i...
Read the whole news AZN - Here's Your Guide to the Coronavirus Vaccine Leaders
News: $AZN 5 Late-Stage COVID-19 Vaccines: Which Is Likely to Be the Biggest Winner?
Pat Benatar's 1980 hit song "Hit Me With Your Best Shot" could have a very different meaning today. People around the world anxiously anticipate a new kind of "best shot" -- a safe and effective COVID-19 vaccine. There are currently 166 novel coronavirus vaccine candidates in development, accor...
In case you are interested AZN - 5 Late-Stage COVID-19 Vaccines: Which Is Likely to Be the Biggest Winner?
News: $AZN Is Moderna Stock a Buy?
All eyes are on the drug manufacturers that are racing to develop the first safe and efficacious coronavirus vaccine. Global COVID-19 cases have crossed the 15 million mark, with at least 634,000 deaths worldwide. In the United States alone, 4.1 million cases have been reported with at least 14...
Find out more AZN - Is Moderna Stock a Buy?
News: $AZN Should Emergent Biosolutions Be Your Next Coronavirus Buy?
Rather than wowing speculators with promises of a scientific breakthrough, Emergent BioSolutions ' (NYSE: EBS) coronavirus strategy positions the company as the go-to resource for vaccine manufacturing support. Aside from its ever-increasing number of contract manufacturing agreements with ma...
Read the whole news AZN - Should Emergent Biosolutions Be Your Next Coronavirus Buy?
News: $AZN 3 Top Pharma Stocks to Buy Right Now
You could make a pretty good case that any time is a good time to buy shares in big drugmakers if you have a long enough investing horizon. Most major pharmaceutical companies generate lots of cash, continually invest in developing new products, and reward shareholders with juicy dividends. But...
Got this from AZN - 3 Top Pharma Stocks to Buy Right Now
News: $AZN Why AstraZeneca Shares Slumped This Week Despite Positive Vaccine News
The news Monday regarding AstraZeneca (NYSE: AZN) 's trial of coronavirus vaccine AZD1222 seemed to be the type of information that would push a stock's price up, not down. Interim results from the phase 1/2 trial of the company's vaccine, which was developed in partnership with Oxford Unive...
Find out more AZN - Why AstraZeneca Shares Slumped This Week Despite Positive Vaccine News
in 2019 the bill and melinda gates foundation invested 55 million to biontech for infectious disease vaccine development.
mixed messages everywhere. why pfizer gets the us gov $$ when astrazeneca and oxford are ahead. horse race for sure.
So I was buzzed and clicking around pre-market last week and bought 500@62 on the hype.
Mistake, sell or hold?
I have not followed AZN so looking for your educated opinions. I’m fine with losing 2500 tomorrow but if u guys think it will pop back I’ll hold.
All of this vaccine pumping is getting exhausting. Buying thin air.
additionally, what companies are outsourcing to other countries (china) for supplies or manufacturing? usa!
agree, you have to wonder their bias. other networks were more positive.
That Bloomberg article is really a false narrative. The only thing that matters is if the vaccine has enough antibodies to prevent infection, not whether it has more antibodies or less antibodies than any other vaccine.
OK seems as though the beer money flippers are boarding again. :)
Followers
|
27
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
298
|
Created
|
10/17/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |